Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

3 1 1 1

What is this study about?

This clinical trial is focused on studying Chronic Obstructive Pulmonary Disease (COPD), a long-term lung condition that makes it hard to breathe. The study will evaluate the effectiveness of a new treatment using a combination of medications delivered through an inhaler. The medications being tested include Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate Dihydrate, which are combined in a product called Trixeo Aerosphere. This combination is compared to another inhaler treatment called Bevespi Aerosphere, which contains Glycopyrronium Bromide and Formoterol Fumarate Dihydrate. Additionally, the study involves the use of Salbutamol, a common medication for relieving breathing difficulties.

The purpose of the study is to assess how well these treatments work in improving heart and lung health in people with COPD. Participants will be randomly assigned to receive one of the treatments or a placebo. The study will last for up to 36 months, during which participants will use the inhalers as directed and attend regular check-ups to monitor their health. The study aims to determine the time it takes for participants to experience severe heart or lung-related events, such as worsening of COPD symptoms or heart problems.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how the treatments affect their condition. The results of this study will help to understand the benefits and risks of using these inhaler medications for managing COPD and improving overall heart and lung health.

1 joining the study

Upon joining the study, participants are required to demonstrate the correct technique for using a metered-dose inhaler (MDI) during the initial visits.

Participants must be between 40 to 80 years old and have a confirmed diagnosis of chronic obstructive pulmonary disease (COPD).

2 initial assessment

An initial assessment includes a blood test to measure eosinophil count and a COPD assessment test (CAT) score.

Participants must have a history of smoking and meet specific cardiovascular risk criteria.

3 randomization

Participants are randomly assigned to receive either the combination triple therapy or the dual bronchodilator therapy.

The combination therapy includes budesonide, glycopyrronium, and formoterol fumarate, while the dual therapy includes glycopyrronium and formoterol fumarate.

4 treatment administration

Participants use the assigned inhalation therapy daily as per the study protocol.

The combination therapy is administered as Trixeo Aerosphere, and the dual therapy as Bevespi Aerosphere, both via inhalation.

5 ongoing monitoring

Participants attend regular visits, either in-person or virtually, to monitor their health and the effects of the treatment.

The study aims to evaluate the time to the first severe cardiac or COPD event, among other health outcomes.

6 completion of study

The study is expected to conclude by March 2028, with participants continuing their assigned treatment until the end of the study period.

Final assessments will be conducted to evaluate the overall impact of the treatment on cardiopulmonary outcomes.

Who Can Join the Study?

  • Participants must be between 40 and 80 years old.
  • Participants must be willing to visit the study site or join virtual visits as needed to complete all study assessments.
  • Participants must show they can use an MDI (Metered Dose Inhaler) correctly at the first two visits.
  • Females can join if they are either unable to have children (permanently sterilized or post-menopausal) or if they can have children, they must have a negative pregnancy test and use a highly effective birth control method.
  • Participants must be able to give signed informed consent, agreeing to follow the study’s requirements and restrictions.
  • Participants must have a confirmed diagnosis of COPD (Chronic Obstructive Pulmonary Disease) with specific lung function test results.
  • Participants must be current or former smokers with a history of smoking at least 10 pack-years. This means the number of cigarettes smoked per day divided by 20, multiplied by the number of years smoked. Former smokers must have quit at least 6 months before the first visit.
  • Participants must have a certain level of eosinophils (a type of white blood cell) in their blood, measured at the first visit.
  • Participants must have a CAT (COPD Assessment Test) score of 10 or higher at the first visit.
  • Participants must meet at least one of the following cardiovascular (heart and blood vessel) disease or risk factor criteria:
    • Have established cardiovascular disease.
    • Have a combination of cardiovascular risk factors such as high blood pressure, diabetes, chronic kidney disease, abnormal cholesterol levels, or obesity.
    • Be at high risk of cardiovascular disease based on a risk assessment tool.
    • Have coronary artery calcification seen on a CT scan.
  • Participants must be willing and able, according to the investigator, to adjust their current COPD treatment as required by the study protocol.

Who Cannot Join the Study?

  • Patients with a history of severe heart or lung problems that are not related to Chronic Obstructive Pulmonary Disease (COPD).
  • Patients who have had a recent heart attack or stroke.
  • Patients with uncontrolled high blood pressure.
  • Patients with a history of severe allergic reactions to medications.
  • Patients who are currently participating in another clinical trial.
  • Patients who are pregnant or breastfeeding.
  • Patients with a history of drug or alcohol abuse.
  • Patients with any other medical condition that the study doctors believe would make it unsafe for them to participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Policlinico “Tor Vergata”, Università degli Studi di Roma TOR VERGATA Rome Italy
Sydvestjysk Sygehus Esbjerg Denmark
Medical University Of Graz Graz Austria
Centre Hospitalier Regional Et Universitaire De Brest Brest France
Azienda Ospedaliero Universitaria Careggi Florence Italy
CHU Grenoble Alpes La Tronche France
Koranyi National Institute For Pulmonology Budapest Hungary
Reseau De Sante Mutualiste Villeurbanne France
Clinical Studies Pankow Berlin Germany
Simplex Kft. Nyiregyhaza Hungary
DCC V Plovdiv EOOD Plovdiv Bulgaria
Rockmed s.r.o. Bratislava Slovakia
ALERGIA, s.r.o. Topolcany Slovakia
INSPIRO s.r.o. Humenne Slovakia
RESPIRO-MEDICAL s.r.o. Kralovsky Chlmec Slovakia
Ospedale dell’Angelo di Mestre Mestre – Venezia Italy
Praxis Erdkampsweg Hamburg Hamburg Germany
Pneumologicum Hanover Germany
Studienzentrum Dr. Tasso Bieler Riesa Germany
Clinique St-Joseph Trelaze France
Bajcsy-Zsilinszky Kórház és Rendelőintézet Monor Hungary
SimpleMed Bt. Vajszlo Hungary
Eszterhai Med Kft. Komadi Hungary
Centro de Atención Primaria Badia del Vallès Barcelona Spain
Centro de Salud Mas Font Barcelona Spain
Centro de Salud Son Pisá Illes Balears Spain
Salus Ustroń Sp. z o.o. Ustron Poland
Primamed S.C. Hanna Świtkowska Barbara Krzywańska Sieradz Poland
Indywidualna Specjalistyczna Praktyka Lekarska Szczecin Poland
Centre Hospitalier De Laval Laval France
Children’s Health Medical Center EOOD Sofia Bulgaria
FARMA -MED. Kujawskie Centrum Medyczne Spółka z o.o.; Inowroclaw Poland
Praxis am Markt Essen Germany
Bispebjerg Hospital Copenhagen Denmark
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
Multiprofile Hospital For Active Treatment Hadji Dimitar OOD Sliven Bulgaria
Trial Pharma Kft. Gyula Hungary
Futuremeds Sp. z o.o. Wroclaw Poland
Krakowskie Centrum Medyczne Sp. z o.o. Cracow Poland
Individual Practice For Specialized Medical Care Dr. Nikolay Kostadinov EOOD Burgas Bulgaria
Osrodek Badan Klinicznych Clinsante s.c. Ewa Galczak-Nowak Malgorzata Trzaska Torun Poland
Gemeinschaftspraxis Dr. med. Josef und Dr. med. Wilma Großkopf Wallerfing Germany
Lungenpraxis – Praxisgemeinschaft Witten Witten Germany

Other Sites

Site Name City Country Status
Multiprofile Hospital For Active Treatment Knyaginya Klementina Sofia EAD Sofia Bulgaria
Karolinska University Hospital Solna Sweden
Sygehus Lillebaelt Vejle Sygehus Vejle Denmark
Azienda Ospedaliero Universitaria Di Modena Modena Italy
Hopital Beaujon Clichy France
Region Stockholm – SLSO Stockholm Sweden
Medicus Services s.r.o. Brandys Nad Labem Czechia
Capio La Croix Du Sud Quint-Fonsegrives France
Hospital Universitario De Cruces Barakaldo Spain
Institutul De Pneumoftiziologie Marius Nasta Bucharest Romania
Pneumologie Schlafmedizin und Onkologie am Diako Elke Dankelmann Bernhard Faderl Sabina Wehgartner-Winkler Michael Heller und Prof. Dr. med. Guenter Schlimok Partnerschaft Augsburg Germany
Danderyds Sjukhus AB Danderyd Sweden
Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen gGmbH Essen Germany
Region Uppsala Uppsala Sweden
Rcmed Oddzial Sochaczew Sochaczew Poland
A.O. Krankenhaus St. Josef Braunau GmbH Braunau Am Inn Austria
CIMS Studienzentrum Bamberg GmbH Bamberg Germany
Zentrum Fuer Ambulante Pneumologische Forschung Marburg GbR Marburg Germany
Specialized Hospital For Active Treatment Of Pneumo-Physiatiric Diseases Vraca /Sbalpfz Vratsa EOOD Vratsa Bulgaria
Centrum Diagnostyczno Terapeutyczne Medicus Sp. z o.o. Lubin Poland
Romed Klinikum Rosenheim Rosenheim Germany
Framol-Med GmbH Rheine Germany
Kardiologische Praxis Wermsdorf Wermsdorf Germany
Utzireupjb Ol Duonvtcv Debrecen Hungary
Vyyeuxxx Cdaysrfm Rknewjer Lommsxn Gryr Luebeck Germany
Lvjjf Guwvnqx Haambmvy Or Awacsh Athens Greece
Suinzmfmzckqkxo Ai Stockholm Sweden
Mmngrqw Cyrtvy Phcwqozlbsp Ljra Sofia Bulgaria
Ucdazxaixy Gkwnspm Hpuzvvud Oj Iorfizys Ioannina Greece
Fedbpzncpt Ilfgg Pseuefvwtbj Spd Mtdruf Pavia Italy
Aitiwqacpa Ppcbfbiz Hgkvvvkv Dd Mygvatpjc Marseille France
Riuyeh Stkot Snnxos Upolwgztjdnmgmxfens Lund Sweden
Aggkyupr Uwngthwpkj Hvpdevrc Lorenskog Norway
Igcpr Owjkdsra Pitwuwtsdpj Sxp Mvmjrin Genoa Italy
Uvpqtlafyotc Dy Sdbhvagq Dw Ccxsrdozer Santiago De Compostela Spain
Acnxyrp Uaiitgokry Heanuaxh Aalborg Denmark
Aeulxns Oviydowuvzm Uknhioienzjsl Fqvlilfk Ia Dx Nabfer Naples Italy
Cswp Dn Nuzok Vandoeuvre Les Nancy France
Gggmvao Uvaszvljyp Hhiofhsw On Pyksur Patras Greece
Antiel Mjwdzkk Cmhyfn Saxa Thessaloniki Greece
Kjchrqcz ddt Uyytwxodzrmd Mmunmgda Als Munich Germany
Boxhqrtmslozghfxuscbyaccggmt Bje Pzan Dys Msl Gmlqozz Houacrhf Dst Mcv Asswrtr Bxlish Gcl Leipzig Germany
Runlyo Ouihwog Lfhz Orebro Sweden
Uhuicmjiff Dmdkr Ssejy Dg Rpls Lz Shzkbqff Rome Italy
Qdqks Sjfjou Codogecod Hkjnidxy &yhiath Sxbezcrdoue Ubgkrirlus Hzjtvmeh &qumngr Vlrsuks Gnvimoamnpilovdtbl Gothenburg Sweden
Gwsxgt Nhynjydqxw Tnubbvghbxinb Gqfuce Pylhvdihflwz Thessaloniki Greece
Mceysesriocvs Hldvensp Fzu Ateyzx Tuyqfkgwv Dxn Scjhza Inkbm Ai Montana Bulgaria
Nbjymrfnu S Plioqycuclas Byeupk Nbou Brezno Slovakia
Tvsuyr Crziie Sxpe Thessaloniki Greece
Htcnnibj Uwwqhpjyggbbu Vxezwi Dm Lbl Nwlmat Granada Spain
Aqvzqrk Sabzc Svodvxsqj Tblezsgudafj Dkb Scsac Lzxne Varese Italy
Cncxzhi Mkknznkr Ojigmbnydo Mwze Slp ju Bialystok Poland
Ajueoo Nqlvm Hejjwchf Athens Greece
Ith Pekyqbbpqcw Gqvz &zqnx Cfu Kw Frankfurt Germany
Hbafuhos Ubstsajacwvhn Vdzorq Dx La Vuohkfhj Malaga Spain
Hdpczrof Uwfklodzmyqlwt Sfhyqwljtx &jguabo Hapkslg dj Htqxsggbdem STRASBOURG, Alsace France
Uvbxcovdnf Gsygefb Hdcjqbjj Aatxhlu Goorxbt Hvuyrntq Os Woqk Aiolmk H Aprd Vptkhzb Chaidari Greece
Cusduw Huracwevull Dq Cgmcob Shdojo Vcjc Cannes France
Cau Cyyri Rffqwdqbuwa Lyon France
Dsvaqrksxp Cqnhxvxgkbrm Cmmqpr Auceqzyae Oye Sofia Bulgaria
Sxvfzsvi Cbzzma Jkvrntmc Df Uzovgtz Bgyjy Oradea Romania
Hrmdjqqz ol Ihpoyjxwmg Ddzvagnr ady Przxpbzeec Vlluhb Bgmoyi Thzjlqlds Timisoara Romania
Mbinen Ghargysadkix Gyongyos Hungary
Cmtzxfm Iqbdntjdwswno Tcgaali Sjl z ogew Piaseczno Poland
Cvd Hlobebo Kujb Encs Hungary
Olbxdjhucz Drt Rflrgx Vacdx Feldbach Austria
Sklafyuxarysku Dga mvdc Szjizucht Peine Germany
Uxpifj Mtdqthf Cuhghp Ezyh Plovdiv Bulgaria
Pwex Mgpcwt Jsmn Vtncm Enenahsxtp Eggachgvajwmc Ijsenolpazk Pecs Hungary
Mecbpvdgo stwpmj Jindřichův Hradec Czechia
Weejjakdni Spvwlec Scpi ibr svg Rxitwp w Cewhplwja Gsfjq Sgfidsalbyvetb Csajmov Cvhmfy Puua Checiny Poland
Crfakb Htymxfiwvzz Bztyr Sugayi Vfrs Blois France
Mdwkkgzpkv Cmlrsy Hhdceftqe Efxe Sevlievo Bulgaria
Suufaso Eiaddectzkd Kmma Kalocsa Hungary
Djk Mbnc Fqpu Beaaqrm Fzokqscz Fmkr Ivtxgp Mjptnql Uml Pdswxbfromn Leipzig Germany
Rcqvrf Ajfgsfyf Mcfg Ae Pernik Bulgaria
Slynyhldgluykz Blcxouh Zg Ageqhoq Lnzzzvoo Nv Pnrccxuukvcbxvuonlfb Zwfmoqhgstim Du Nylzwp Ppehdmmlkjerwwmxhi Ects Pazardzhik Bulgaria
Plohaj aoscvptrj Kbkcqez shcuxd Kralupy nad Vltavou Czechia
Cnxy Aqzwvy Pymvcw Sdw z ovlk Warsaw Poland
Zofzfwu Msrwetk Csqkdq Sqf z oqtb Lublin Poland
Maswoia Ckgmjg Sks Iqde Ronqxu Ekiw Vidin Bulgaria
Emzoexxl Snf z oxlx Karczew Poland
Poxyvaszp 2jsm Mngml Stara Zagora Bulgaria
Pieizahgywklosh Srefechdqvaywm Mtc dmibwdbhqgwhjbp Berlin Germany
Birwwg &aywo Mdua Cvb Kfuz Budapest Hungary
Dlehiofdutwiw Kefexrfityrvq Ttdwcyw 1 Hqdecac Elfo Haskovo Bulgaria
Msndpiv Cmcigf Ddvitfzj 2vmj Eivq Yambol Bulgaria
Cln Mtk Combvj Plock Poland
Psxrla aqmlgvtjx Rxrtkgfs Rokycany Czechia
Oaaztgpd cydydb pqfrtkwy sccenp Prague Czechia
Pdegsl ag djo Ozhb Berlin Germany
Cl Pxvjos Bpjvly Mlu Timisoara Romania
Onwklmjd pta tqa a rwvezywxvr noilrw swxbpm Olomouc Czechia
Nbwc Pnuftpgx Coipng Pakf i Aajkrghxyct Slupsk Poland
Syjddtfs Dn Ppaflbmbndtsmkqvi Lthugr Regiunea Oltenia Romania
Nlg Shg Jemdyg Buqfsnud nzhr Bardejov Slovakia
Ncxicj Lilbccpwef Höllviken Sweden
Pflzyt Dkv mwcz Sdadwrpwg Blopjhm Moers Germany
Lquklrxnkaco Niftmjhr Hamburg Germany
Lupfvxfpztisvnvs Hikaqcxisnp Berlin Germany
Hyjmvilk czvshx Hsyff Mmzfts io Avigamxd Aurillac France
Mvysjkx Cfctgi Hpzmnn Cjay Ojg Sandanski Bulgaria
Tdhkzkzr Drvt Jywc Kgjmhy Tapolca Hungary
Vymqasgya tcivqfqdlwqq Helsinki Finland
Crvbmb da Swolt Cydqhjvz Cantabria Spain
Rnjqb Hkgil Ityysvnjlsqqyfjccrqhqqukqycpwj Sejldmhtirdohvw Gwaifag Lshmpgop Libiąż Poland
Cwq dqjygnrgjoeyst Epagny Metz Tessy France
Mptnvpw Cqwhxf Hlpcvi Raee Ldxs Ruse Bulgaria
Pqymx Pzhculw Kson Budapest Hungary
Kspcisobb sykazd akf hqsnty cyby chvbwh Kangasala Finland
Su Coeijqft Dabgufkost Scpnsg Timisoara Romania
Czskgky Ppcdvs Spu Bucharest Romania
Rjvwnfuv Iu Akzrd &ihyimh Clmtmwg Iiiltklefl De Pocockbtrjn Negresti-Oas Romania
Obviod Efnkrgpfbjoln Cbfmihp Kodp Dunaújváros Hungary
Falrhubsjk Grms Offenbach Am Main Germany
Awnhomw Swz z ozts Poznan Poland
Pbjcja Gmymmkxn Gfoyze Mtrnazy Kdcevmil sweh Sosnowiec Poland
Gtlgxhmhvq Dyu Hrqzmmhq Dp Leyfxatsdnjxlzdj Ctasqyyvkg Dh Lvwdj Lomme France
Dsedniyby Cmtmforf Da Srufxnw Dq Snbof Dcj Andeun Toulon France
Zwih Js sjqovo Levice Slovakia
Fvadwdrbe Ivygo Brest France
Kizskkxpnewc Ktpd Kecskemet Hungary
Voqozq Vdylw Hx Drammen Norway
Uhekoiriwoyokcdwd Clnujn Bzmujteffe Da Roxs Rome Italy
Aildjzi Osaewwmgrdj Udfwqgtxfjwsq Sfutxc Siena Italy
Pkaomy Srzl Skorzewo Poland
Sjgxigdby Gmyi Hanover Germany
Kadahinyy Frhznsuyv Bvsosn Gmq Berlin Germany
Tynonasspvqfdvitv Tvmbmyvgvazjv Torokbalint Hungary
Alfwjskdjxb Kpss Szazhalombatta Hungary
Aovbho Ae Stockholm Sweden
Apbtwhk Unlhb Sgowholgj Ldeoqm Upfzrc 1 Perugia Italy
Miqbldd Mataró Spain
Cjzpfd Hzmqbgnrclb Bnhqiufg Avvmgubzzh Vannes France
Kogw Rmxkds Kxdvhi Ei Rolsrfxbgoqvsw Edeleny Hungary
Ghlkje Hidvvatiphy Dq Lq Rkdeky Dk Mdxzxblz Ef Set Autaiy Mulhouse France
Rrqax Mlo Ktei Szekesfehervar Hungary
Sarcedu On Kuopio Finland
Rqnzog Gusllewt Dh Stocr Bayonne France
Cpbmuv Hhcvequlmbg Urrpiplpcbtwn Rpumg Reims France
Htfklvn Ebbuotao Mxzuwvqar Marseille France
Azqfyvr Onyrvmfsqufvsonncnsyszwua Sdch Awogl Rome Italy
Iphbv Ikkyy Irdzddke Nnwqaxwbn Db Rthwlhru E Csbb Pou Afmfigm Ancona Italy
Rzszmt Vrqxzdnqopbqb Umea Sweden
Pnehmrdwxws spjsuv Olomouc Czechia
Hyeajwcn Hpaxfsvw Hvidovre Denmark
Nzrvmdu Haykqhcu Næstved Denmark
Erumh Uhtedtxzhs Eijubgwfz Hhnhpxix Bucharest Romania
Sfm Ouyuh Hftyomep Hc Trondheim Norway
Ochqzgersmio Cldkjji Mpcqsowy Anhm Ovkgs Cvdvyc Khdofmucn Cwygws sorb Ostrowiec Swietokrzyski Poland
Mwsd Mmpvrdk aiz Cnprxhxo Sbuqjym Cmamawh Gqvg Cottbus Germany
Jjioruexinfjyagwnpal Vjdxknwxn Hftddze Gpqb Kzimifcxxfqlvtlnospco Szolnok Hungary
Hurrwdda Usffxfdfymbcy Ixeygep Lesesy Madrid Spain
Plljeh Prkeyk Rcqvlcmcrh Sky jk Cracow Poland
Cppkyqze Bift Sgogluwxx Swx z oose Stoc Lublin Poland
Hcisecqx Urevmhwxlcohe Dz Pfeae Ahhrxpoqvg Valencia Spain
Pwx Fbzrlti Avtdda Suj z ocbg Katowice Poland
Haxctwkt Qwtpohownhh Mnhrsuvh Marbella Spain
Kewiwdiptfn Bqqvkscpo gblfp Solingen Germany
Cbb Ohnfxmx sgzsiu Moravska Ostrava A Privoz Czechia
Lyd Hgpnjbqw Ds Cytpgoba Le Coudray France
Cjfhce Do Spkuz Cnezu Mcywhla Aeldtcf Mzaf Fmoztdmmf Cabra Spain
Remntz Hqxnfyl Varberg Sweden
Dkq Kzrq Balatonfured Hungary
Sbkuaknyjxlsyst Pgqqzipubvi Lpfbekdi Avitrq Mcr Stx z odrg Poznan Poland
Ptuamwu i Lzgt Av Lund Sweden
Swvycguj Cnyhxg Dl Pdffshgjaevopkkyl Lvqs Ditoymfn Cluj Napoca Romania
Lkhvagx Sbovrqrylnu Jq Mpfokvmrbl I Pilmikxzs Wroclaw Poland
Pmpucjc Bpwkcl Ssdtnhg Gkmd Berlin Germany
Suzfxstskib Hexcekdk Fqz Akrhzr Tyjmiztdn Og Pikgecvuxkwzynhxhpl Dbjvadbm Dei Dgxauas Gyydbeguzcsowpu Ruse Bulgaria
Ejusuazg Gzqxlmjkeh Kzhw Godollo Hungary
Phivfn Samoqjt Dxiwfithz Gdyy Darmstadt Germany
Azgdymegp Myvfhel Cznhwq Ojp Dupnitsa Bulgaria
Mbulfauqccdi Hamvjzhi Fpu Akuzjr Tkjwihalnjdkn Hrrdfwdk Lbuu Panagyurishte Bulgaria
Mmebbueasodey Hqaaqrwx ffr Agiukm Tymvsuidw Hnwnl ary Bvgye Ebd Pleven Bulgaria
Cppsoj Dvghiyx sevsit Krbnrd Kosice Slovakia
Srmgmge Mptjulhyhf Stgvqc Ag Skedsmokorset Norway
Mhrbespsbkd Stzomk Milan Italy
Npxk Eyojf Sla z oiqa Bialystok Poland
Cgzkwt Hrdgcmxyiqi Db Pdkf D Aks Cwivff Hdmvvzepxlm Ihwtbnhmilvbz Agliqdzjwzo Aix En Provence France
Cnaoab Hzzyhkjwsco Pbnsdx Dl Cwvqmuxh Cherbourg-En-Cotentin France
Mrhndte adpc Prague Czechia
Nkdkpnikc Toyen acue Tabor Czechia
Mnvc Rracjxlz Gsji Berlin Germany
Gtfdevj Ildaobzok Stolrr Barcelona Spain
Bgirgiz Cdjiumeo Sld z oxvq Kielce Poland
Sxcmveab Cqmasb Jyqiwfbn Mbltx Targu Mures Romania
Syopun Tlqojsspsop Od Turku Finland
Dkmnyikqsi Chajehjtmhfx Cjtegn Emzdio Ovi Varna Bulgaria
Eyew Cbtyfyf Uscqn Mjymqwfgjo Eta Śgnpyid Rzeszow Poland
Awcgjumjs Mrq Bigjod Gwtr Landsberg Am Lech Germany
Hazjgjavzk Vjtdmi Ojkqakrnkpdpc Hajdunanas Hungary
Pbjqhaxqbnwes Ejblccaeacbs Slubyijyguv Nqrwlsfzw Kthg Puspokladany Hungary
Oewjsfwrpx Xboto Lymqw Bad Ischl Austria
Ieqirajg fbe Apitshad utw Auqsmztxhycqxfz Bnzmai Berlin Germany
Mzmvcwryueju Hjuyeclf Fpq Almbxt Tedybpdsl Mhbcitp Cueejln Sptyf Iyoj Rnhkio Ewks Plovdiv Bulgaria

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Recruiting
23.07.2024
Bulgaria Bulgaria
Recruiting
23.07.2024
Czechia Czechia
Recruiting
23.07.2024
Denmark Denmark
Recruiting
23.07.2024
Finland Finland
Recruiting
23.07.2024
France France
Recruiting
23.07.2024
Germany Germany
Recruiting
23.07.2024
Greece Greece
Recruiting
23.07.2024
Hungary Hungary
Recruiting
23.07.2024
Italy Italy
Recruiting
23.07.2024
Norway Norway
Recruiting
23.07.2024
Poland Poland
Recruiting
23.07.2024
Romania Romania
Recruiting
23.07.2024
Slovakia Slovakia
Recruiting
23.07.2024
Spain Spain
Recruiting
23.07.2024
Sweden Sweden
Recruiting
23.07.2024

Trial locations

Budesonide is a medication used in this trial as part of a combination therapy. It is a type of steroid that helps reduce inflammation in the lungs, making it easier to breathe for people with chronic obstructive pulmonary disease (COPD).

Glycopyrronium is included in both the combination and dual therapies in this trial. It is a bronchodilator, which means it helps open up the airways in the lungs, making breathing easier for patients with COPD.

Formoterol Fumarate is another medication used in both the combination and dual therapies. It is a long-acting bronchodilator that helps relax muscles in the airways to improve breathing in people with COPD.

Chronic Obstructive Pulmonary Disease (COPD) – This is a long-term lung disease that makes it hard to breathe. It is characterized by a persistent blockage of airflow from the lungs, leading to breathing difficulties. The disease progresses slowly and is often caused by long-term exposure to irritating gases or particulate matter, most commonly from cigarette smoke. Over time, symptoms such as chronic cough, mucus production, and wheezing may worsen. As the disease advances, individuals may experience increased breathlessness and fatigue. COPD can lead to frequent respiratory infections and may significantly impact daily activities.

Trial ID:
2023-507407-59-00
Protocol code:
D5989C00001 THARROS
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

    Recruiting

    4 1
    Investigated Drugs:
    Czechia Germany Greece Lithuania The Netherlands Norway +4
  • Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

    Recruiting

    4 1
    Investigated Drugs:
    Belgium Denmark Estonia Finland France Germany +7